ELI LILLY & CO (1LLY.MI) Stock Price & Overview

BIT:1LLY • US5324571083

835.5 EUR
-28.8 (-3.33%)
Last: Mar 5, 2026, 07:00 PM

The current stock price of 1LLY.MI is 835.5 EUR. Today 1LLY.MI is down by -3.33%. In the past month the price decreased by -6.16%. In the past year, price increased by 5.77%.

1LLY.MI Key Statistics

52-Week Range535.2 - 972
Current 1LLY.MI stock price positioned within its 52-week range.
1-Month Range812.4 - 944.7
Current 1LLY.MI stock price positioned within its 1-month range.
Market Cap
789.865B
P/E
40.09
Fwd P/E
28.92
EPS (TTM)
20.84
Dividend Yield
0.68%

1LLY.MI Stock Performance

Today
-3.33%
1 Week
-5.36%
1 Month
-6.16%
3 Months
-8.57%
Longer-term
6 Months +36.97%
1 Year +5.77%
2 Years +16.45%
3 Years N/A
5 Years N/A
10 Years N/A

1LLY.MI Stock Chart

ELI LILLY & CO / 1LLY Daily stock chart

1LLY.MI Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to 1LLY.MI. When comparing the yearly performance of all stocks, 1LLY.MI is a bad performer in the overall market: 68.92% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
1LLY.MI Full Technical Analysis Report

1LLY.MI Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to 1LLY.MI. While 1LLY.MI belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
1LLY.MI Full Fundamental Analysis Report

1LLY.MI Earnings

On February 4, 2026 1LLY.MI reported an EPS of 7.54 and a revenue of 19.29B. The company beat EPS expectations (11.92% surprise) and beat revenue expectations (6.36% surprise).

Next Earnings DateApr 30, 2026
Last Earnings DateFeb 4, 2026
PeriodQ4 / 2025
EPS Reported$7.54
Revenue Reported19.292B
EPS Surprise 11.92%
Revenue Surprise 6.36%
1LLY.MI Earnings History

1LLY.MI Forecast & Estimates

37 analysts have analysed 1LLY.MI and the average price target is 1038.08 EUR. This implies a price increase of 24.25% is expected in the next year compared to the current price of 835.5.

For the next year, analysts expect an EPS growth of 38.64% and a revenue growth 28.68% for 1LLY.MI


Analysts
Analysts80.54
Price Target1038.08 (24.25%)
EPS Next Y38.64%
Revenue Next Year28.68%
1LLY.MI Forecast & Estimates

1LLY.MI Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

1LLY.MI Financial Highlights

Over the last trailing twelve months 1LLY.MI reported a non-GAAP Earnings per Share(EPS) of 20.84. The EPS increased by 86.23% compared to the year before.


Income Statements
Revenue(TTM)65.18B
Net Income(TTM)18.41B
Industry RankSector Rank
PM (TTM) 30.99%
ROA 16.02%
ROE 77.38%
Debt/Equity 1.72
Chartmill High Growth Momentum
EPS Q2Q%41.73%
Sales Q2Q%42.56%
EPS 1Y (TTM)86.23%
Revenue 1Y (TTM)44.7%
1LLY.MI financials

1LLY.MI Ownership

Ownership
Inst Owners83.09%
Shares945.38M
Float943.27M
Ins Owners0.16%
Short Float %N/A
Short RatioN/A
1LLY.MI Ownership

About 1LLY.MI

Company Profile

1LLY logo image Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The firm is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. The company is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). The company is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.

Company Info

ELI LILLY & CO

Lilly Corporate Ctr, Drop Code 1094

Indianapolis INDIANA US

Employees: 47000

1LLY Company Website

1LLY Investor Relations

Phone: 13172762000

ELI LILLY & CO / 1LLY.MI FAQ

What does 1LLY do?

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The firm is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. The company is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). The company is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.


What is the stock price of ELI LILLY & CO today?

The current stock price of 1LLY.MI is 835.5 EUR. The price decreased by -3.33% in the last trading session.


What is the dividend status of ELI LILLY & CO?

ELI LILLY & CO (1LLY.MI) has a dividend yield of 0.68%. The yearly dividend amount is currently 4.82.


What is the ChartMill technical and fundamental rating of 1LLY stock?

1LLY.MI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Would investing in ELI LILLY & CO be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 1LLY.MI.


Can you provide the ownership details for 1LLY stock?

You can find the ownership structure of ELI LILLY & CO (1LLY.MI) on the Ownership tab.